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OBJECTIVES:  
To study the burden of osteoporosis, osteopenia and metabolic abnormality related to bone 
health in male patients with chronic obstructive airway disease in the age group between 40 
to 70 years who are being followed up in Christian Medical College, Vellore. 
METHODS: 
Clinical methods: 
This was a cross sectional study done over a period of two years at Christian Medical college 
Vellore. A detailed history and physical examination was done for all male patients with 
chronic obstructive pulmonary disease in the age group between 40 to 70 years, who were not 
on bone medications. Blood samples were collected for calcium, phosphorous, albumin, 
alkaline phosphatase, creatinine, parathormone, 25-hydroxy vitamin D and testosterone. Lung 
functions test and six minute walk test were performed.  Bone mineral density was assessed 
using DXA scan (dual energy x-ray absorptiometry). 
Statistical methods: 
Continuous variables were described using mean and standard deviation, if normally 
distributed. Interquartile range was used for skewed distribution. All categorical variables 
were summarized by using frequencies and percentages. Logistic regression model was 
constructed to assess the relationship between parameters showing positive correlation with 
osteoporosis in COPD (chronic obstructive pulmonary disease). 
RESULTS:  
A total of 67 patients were enrolled. The prevalence of osteoporosis among the male COPD 
patients was 61% (41/67) and an additional 33 %( 22/67) had osteopenia. The prevalence of 
metabolic bone abnormalities in patients with COPD were: vitamin D deficiency in 69 %( 
46/67), hypocalcaemia in 4 %( 3/67), raised alkaline phosphatase in 8% (6/67) and elevated 
parathormone in 31 %( 21/67). The factors which showed a trend towards adverse bone 
health were: advanced age and low body mass index. Although these variables showed a 
positive trend towards osteoporosis in COPD patients, they did not achieve statistical 
significance. 
CONCLUSION:  
In this study the prevalence of osteoporosis and osteopenia among male COPD patients were 
61% and 33% respectively, which is noted to be almost twice the prevalence as that of the 
general population.  
KEYWORDS:  Chronic obstructive air way disease; osteoporosis; osteopenia; vitamin D 
deficiency 
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INTRODUCTION 
 
Chronic obstructive airway disease (COPD) is a major cause of health care burden all over the 
world and the only leading cause of mortality that is increasing in prevalence(1). It is one of the 
diseases that have significant impact on the development of the country as it affects the majority 
of the working male population in their prime group and causing significant disability.  COPD 
is a systemic diseases characterised by multisystem affectation. It affects all the system in the 
body and the damage caused is irreversible.   Although the most common system affected is the 
cardiovascular system, the system that is ignored is the bone.  
 
Bone one of the largest organ in the body is affected by COPD. It may be directly because of 
the disease or its treatment effect. The constituents of the cigarette smoke which is described in 
later directly causes the death of the osteocytes. Both the underuse and overuse of the steroid for 
the treatment adversely affect the bone health. The underuse of the steroid leads to poor disease 
control with systemic spill over of the inflammation and decrease activity which in turn lead to 
poor bone health. The overzealous use of steroids due to multiple effects adversely affects the 
bone health.  
 
The effect of COPD disease on the bone health is extensively studied in the developed nation. In 
India there was no study published during the start of this dissertation about the bone health in 
COPD.  There were few studied the osteoporosis in patient with COPD but other aspects of the 
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bone health was not assessed in these studies.  What we have tried is to assess the COPD and 
the treatment as a whole affecting the bone health.  This will give a picture of the disease with 
its treatment affecting the one of the largest tissue in the body.  This help assessing the 
prevalence of adverse bone health in patient with COPD and the factors affecting it.  This will 
help the clinician greatly to look for the adverse predictors and treat at the early stage to prevent 
the irreversible damage.  
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AIMS 
 
To assess the prevalence of adverse bone health in patients with chronic obstructive pulmonary 
disease and associated factors that may contribute to it, among the patient seen in the 
outpatient department in a tertiary care centre in India. 
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OBJECTIVES 
 
 
1. To study the burden of osteoporosis and osteopenia in male patients in the age group between 
40-70 years with chronic obstructive airway disease who are newly diagnosed or on follow up 
with Department of pulmonary medicine at Christian Medical College Hospital Vellore, 
Tamilnadu, India 
 
 
2. To study the existing metabolic abnormality related to bone health in the same population. 
 
 
3. To assess the determinants of adverse bone health in the population being studied 
 
 
 
4. To make recommendations based on the findings. 
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REVIEW OF LITERATURE 
Chronic obstructive pulmonary disease (COPD) is known to the mankind for the last 400 years. 
The first known description of COPD goes as back as 1679, when Theophile Bonet described 
19 cases where the lung was turgid with air(2).  Subsequently there were number of authors 
describe the disease in different terms based on the local risk factors and the clinical 
presentation. It was in the early 1960s after the two landmark meeting –“Ciba Guest symposium 
in 1959” and “American Thoracic Society 1962”, defined the individual component of the 
disease. It was Dr William Briscoe, who defined the term COPD in the ASPEN Emphysema 
conference held in 1965. The spirometer was invented by Dr John Hutchinson as early as 1846. 
But till 1970 COPD was defined only in pathological terms in the post-partum studies.  It was 
not until late 1990s that the consensus was developed to use the Spirometer to define COPD. It 
is a major breakthrough by the time patient develops the clinical signs of the disease the disease 
had already advanced to the state of irreversibility.  It is killer disease with very high morbidity 
and mortality.  The Global Initiative for Chronic Obstructive Lung Disease (GOLD), was a need 
of an hour initiative by the authority on world health- World Health Organisation (WHO) and 
National Heart, Lung, and Blood Institute (NHLBI) in 2001(2).   
The Global Initiative for Chronic Obstructive Lung Disease (GOLD, has defined COPD as a 
preventable and treatable disease with some significant extrapulmonary effects that may 
contribute to the severity in individual patients(1). The respiratory system affectation is 
characterised by both obstruction to the air flow in and out of the lung with diffusion restriction 
with certain phenotypes of COPD. The characteristic of the COPD is that the airflow 
obstruction is not reversible unlike in bronchial asthma where the airflow obstruction is 
reversible after the trial of the bronchodilator and it is usually a progressive disease. The 
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progressive nature is due to an abnormal inflammatory response of the lungs to noxious 
particles or gases.  
The GOLD has classified into four stages (Table 1)(1).  The classification is based on the 
patient with the symptoms or with risk factors of COPD with the measurement of Forced vital 
capacity and forced expiratory volume in one second (FEV1) before and after the administration 
of the bronchodilator. The characteristics symptoms of COPD are dyspnoea, chronic cough and 
sputum production. The dyspnoea of COPD is characteristics which is progressive, persistent 
and worsens over time and exercise. The condition is characterised by frequent exacerbation.   
The risk factors for COPD are tobacco smoke, house hold smoke, dust and industrial pollution. 
There is also small group of patients who are congenitally predisposed to COPD like patients 
with α1-antitrypsin deficiency. It’s the combination of these risk factors and abnormal 
inflammation that causes irreversible damage to the airway.  
 
Table 1 GOLD staging of COPD. (FEV1-Post dilator Forced expiratory volume at 1st minute, 
 FVC- forced vital capacity)
GOLD Stage Spirometry 
I FEV1/FVC <0.7 and FEV1 80% predicted 
  
II FEV1/FVC <0.7 and 50% FEV1 <80% predicted 
  
III FEV1/FVC <0.7 and 30% FEV1 <50% predicted 
  
IV FEV1/FVC <0.7 and FEV1 <30% predicted 
or 
FEV1 <50% predicted with respiratory failure or Cor pulmonale 
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The salient feature of COPD is its significant extrapulmonary component which is very well 
emphasized in the current GOLD 2014 and it previous definition of COPD(1). More the 65% of 
the patient is characterised by atleast one extrapulmonary system affectation (3).  The 
commonest extra-pulmonary system affected and which are extensively studies are the 
cardiovascular system characterised by systemic and pulmonary artery hypertension, congestive 
cardiac failure and arrhythmias. The other extra-pulmonary manifestations were increased risk 
of diabetes, metabolic syndrome and osteoporosis. 
Global problem of COPD  
 COPD is a health problem with significant medical, social and financial impact on society.  It 
has multiple adverse outcomes both to the patient, his family and the health system of the 
country. In patient’s point of view, COPD causes physical disability, reduced quality and 
quantity of life. In relation to the health care system, it causes very high resource utilization, in 
terms of recurrent office visits, frequent hospital admissions due to acute exacerbations, and 
long term therapy (eg, long-term oxygen therapy, medication)(1).  
COPD is underreporting grossly both in the developed and developing nation. It is because of 
the following  
1. Symptoms of COPD which has frequent overlap with other pulmonary disease like 
pneumonia, asthma, etc. 
2. Clinical signs appear late in the disease 
3. Risk factors are common as smoking is common for number of pulmonary and extra 
pulmonary disease 
4. Cost of diagnosis of the disease is high even in the developed nations 
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The prevalence of smoking is although high but it is underreported. The prevalence of COPD is 
even more under reported as compared to smoking. The prevalence of COPD worldwide is 
15%-20% among smokers(4).The global estimate by WHO shows, 65 million people have 
moderate to severe chronic obstructive pulmonary disease (COPD). More than 5% of the death 
worldwide is attributed to COPD which is equivalent to 3 million, of which 90% occur in the 
low and middle income countries. These data are from the high income countries. Even in those 
countries, the predicted prevalence of the disease is low due to various factors as mentioned 
above. It ranks 4th in the disease causing mortality and ranks 12th-leading cause of disability-
adjusted life years (DALYS, defined as  the number of years lost due to ill-health, disability or 
early death‟) in 1990. It is expected to become 5th by 2020(5). Although COPD was considered 
more common in males but this demarcation in the gender is fading due to the increased 
exposure to tobacco smoke –both active and passive among women and increase in the indoor 
air pollution in developing nation like biomass fuel smokes. 
 
Indian scenario of COPD 
COPD is grossly underreported in India. The earlier studies which were conducted to assess the 
burden of COPD were small surveys, which varied in their methodology, tools and were 
difficult to interpret in resource poor setting. Based on these studies the prevalence rates vary 
from 2% to 22% in men and 1.2% to 19 % in women(6).  These studies were based on the 
unvalidated questionnaires. Some studies also used house hold interviews with peak expiratory 
flow rate as the standard to make diagnosis of COPD. But the disease remained grossly 
underreported.  The burden was steadily increasing warranting high quality nationwide analysis. 
It remained the challenge and it was the Indian Council of Medical Research (ICMR) took this 
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initiative and studied the epidemiology of this disease. The study was sponsored by the Indian 
study on Epidemiology of Asthma, Respiratory symptoms and chronic bronchitis 
(INSEARCH). This nationwide survey included 4-centres in the Phase I and 12 new centres in 
the Phase II study.  
 
The results of the Phase I ICMR study were from Chandigarh, Delhi, Kanpur and Bangalore. 
This reported the prevalence rates of 5.0 and 3.2% respectively in men and women(7). An 
interesting comparison of this study with earlier studies shows the following  
1. The prevalence rate of the disease (COPD) was almost the same i.e., overall 5% 
prevalence has been present in the earlier studies too. 
2. India has doubled its population in the last three decades and hence the total burden of 
COPD has risen to 14.84 million in 2011 from earlier 6.45 million in 1971.  
 
In India the disease is significantly more among Men and the Male to female ratio is distinct in 
Indian compared to the Western figures. This can be attributed to the cultural setting and male 
predominance of smoking(8). Although this ratio is slowly getting blurred due to non-cigarette 
particles from the pollution from different sectors contaminating the environment.  And there is 
a significant contribution from the indoor smoke due to the biomass fuel use to which people in 
household are greatly exposed. This is particularly concern for the Women who are maximally 
exposed to this pollution. There is also a concern of passive smoking in the household contact 
for the Children and Women who may not be active smokers themselves(9). Although we know 
have the prevalence of COPD in India but the effect of the disease on the direct mortality still 
not yet clear.  The limited data obtained from the Rural Household Survey and also Death 
Certification data provides an estimate of around 0.57million deaths were attributed to COPD in 
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1998.  It was second most common cause of death after injuries among the non-communicable 
disease with an estimate of 0.57 million death in 1998(10). Similar but increasing figure were 
quoted in the NFHS I and II surveys.  But we need more robust study to assess the COPD 
disease and its mortality effect. It’s not only the mortality that affects the people but the 
significant disability it cause in terms of both health related and the non-health related ones. The 
financial aspects of this disease are alarming with increasing cost. The direct cost of care for 
COPD patient with stable disease is Rs 2440 as a direct per capita expenditure. And the indirect 
cost of care as one would expect is would the three times high as the direct cost. COPD hence 
not only kill people but also cripples them both medically and socially either directly or by its 
influence to affect the other system in the body. 
Aetiology of COPD: 
The important etiological factor attributed cigarette smoke. Both the particulate and non-
particulate smoke has been attributed to the development of the disease. The most intruding 
aspect of the disease is the only 15% of the significant smokers develop COPD.  And this 
percentage increases up to 50 % in the age group above 75 years old(11).  There must an 
individual risk factor that would have predisposed to the disease either genetic or acquired. The 
other acquired risk factors were biomass fuel smoke, environmental toxic smoke from the 
industries and other particulate smoke. The pure individual genetic predisposition is seen only 
in very few cases like in patients with α-1 antitrypsin deficiency.  Although there are multiple 
other genes were identified but their disease association has been the subject of controversy. 
Lower respiratory tract infection during childhood may increase the airway responsiveness to 
the offending agents(12). 
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Pathology of COPD: 
COPD affect all the part of the lungs although the area most affected are the airway, the 
following area shows pathological changes in the autopsy study of the COPD lung in the 
decreasing order of frequency(13)  
1. Both proximal and peripheral airway  
2. Lung Parenchyma  
3. Pulmonary micro and macro circulatory changes  
These region shows infiltration lymphocytes which are predominantly CD8+ cytotoxic T-
lymphocytes(14).  The other players in the immunity circles are the macrophages and B-
lymphocytes. These inflammatory cells induce secondary changes in the airway epithelium 
producing goblet cell hyperplasia, squamous metaplasia and increase in the size of the sub-
mucosal glands(15).  During the long run because of the repeated injury and healing, it produces 
fibrosis of the wall indicating the irreversible nature of the disease. The fibrosis is 
characteristically in the peri-bronchial in location.  
Pathogenesis of COPD: 
COPD is an inflammatory disease characterised chronic and progressive airway inflammation. 
The triggering event is not very clear but is assumed is to be due to cigarette smoking in the 
genetically predisposed individual. The sequences of events in the COPD lung that lead to 
disease are as follows(16)  
1. Presentation of antigen by the naïve dendritic cells and macrophages –the antigen is in 
question is multiple and the most common is the particulate smoke in the cigarette 
smokers 
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2. The antigen is presented to the naïve T-cell in the lymph node  
3. The T-cell response characterised by the infiltration of the airway epithelium with 
cytotoxic CD4+ lymphocytes and macrophages. 
These cause infiltration of inflammatory cells and necrosis of the airway epithelium caused due 
to the proteolytic enzyme secreted by these cells (Figure 1).  The abnormal inflammatory 
response is attributed to the genetic polymorphism in the gene expression activating these 
enzymes (Table 2)(17). 
 
 
 
Figure 1 Pathogenesis of COPD (TNF-Tumor necrosis factor, NF-Nuclear factor, IL-
Interleukin, LTB-Leukotriene B and TGF-transforming growth factor) 
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Table 2: Gene involved in the pathogenesis of COPD (Matrix metalloproteinase, TIMP-
Tissue inhibitor of MMP, SERPINA-gene coding for antitrypsin) 
Gene/Protein Polymorphism ID Gene ID 
MMP9 CR994492 4318 
MMP1 rs1799750 4312 
MMP12 
 
4321 
TIMP2 rs2277698 7077 
SERPINA3 rs4934 12 
 
 
COPD is a systemic disease: 
GOLD has defined COPD as a systemic disease with significant extrapulmonary effects. It took 
many years for this understanding of COPD as a systemic disease. The commonest cause of 
death and increased morbidity is most often due to it systemic effect like increase in the 
cardiovascular disease and metabolic abnormalities in patient with COPD(18).  The problem 
arises in differentiating this systemic effect of COPD from the shared risk factor between the 
systemic disease and COPD (Figure 2).  A patient with risk factor of smoking could have 
increased risk of atherosclerotic cardiovascular disease and COPD because of the shared risk 
factor between the two.  This confusion should not jeopardize the clinical care of these patients. 
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This difficulty is defining co-morbidity from systemic effect is not only present in COPD in fact 
present in almost all disease. The definition of co-morbidities and systemic cannot be strictly 
applied to COPD as there is multiple shared risk factors. Indeed it was right defined by the 
GOLD as COPD is the systemic disease rather than isolated pulmonary disease(1). 
 
Figure 2 : Diagram showing the relationship between systemic effect and co-morbidities 
 
The evidence for the increase in co-morbidities in patient with COPD was shown by Mapel et al 
who showed that an average of 3.7 co-morbidities were present in COPD patient compared to 
the controls who had an average of 1.8(19).   The co-morbidities that were present in this cohort 
of patient were heart failure, metabolic syndrome, sarcopenia, osteoporosis and depression.  
Similar result was shown by Crisafulli et al that patient enrolled for pulmonary 
rehabilitation(20). They found that there were atleast one co-morbidity was present in 62% of 
the patient.   
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The commonest co-morbidities that was found to be significant in multiple studies were listed 
below  
1. Dyslipidaemia  
2. Diabetes mellitus, 
3. Systemic Hypertension, ,  
4. Chronic heart failure  
5. Coronary artery disease, and  
6. Osteoporosis 
These above six contribute to the total of 86% of the co-morbidities detected in various studies. 
In a landmark trial ECLIPSE which studied the co-morbidities in COPD patient found the 
following results(21) 
1. The three groups were compared –Smoker with proven diagnosis of COPD, smoker 
without COPD and non-smoker 
2. The prevalence of the co-morbidities were 38%, 23% and 16% respectively in the above 
groups with p<0.001 
3. Air flow limitation did not influence the prevalence of these co-morbidites 
The presence of co-morbidities has adverse impact on the disease with respect to mortality and 
also morbidity. It is very difficult to differentiate between the co-morbidities and the systemic 
effects. As noted in another trial 67% of the COPD patients have atleast one systemic organ 
dysfunction(3).  
What cause this systemic dysfunction? There is no direct answer to this question. But there have 
been some postulates. The two important which is widely accepted are  
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1. Systemic spill theory 
2. Compartment model 
Systemic spill theory states that there is spill of the cytokines from the chronic inflammation in 
the airway epithelium(22).  The evidence to support this theory comes from the studies 
indicating the increase in surfactant D protein which is produced only from type II pneumocytes 
is increased in the systemic circulation in patient with COPD. The surfactant D protein helps in 
the innate defence system in killing micro-organism.  But this is not consistent across other 
studies(22).   The compartment model states that there is two or more compartment of which 
one must definitely be pulmonary causing COPD and there is the distant organ affected due to 
the shared risk factor between COPD and other disease.  The distant organ affected as 
mentioned earlier were cardiovascular system, metabolic abnormalities and bone(23).  This 
thesis focuses on bone health in patients with COPD and factor contributing the adverse bone 
health.  The main determinant of the bone health is adequate mineral and remodelling. The 
deficiency of the mineral leads to number of condition of which an important the important one 
is osteomalacia and increased resorption lead to the porous bone named with a condition called 
Osteoporosis.   
This thesis focuses on different aspects of the bone health in patients with COPD. 
OSTEOPOROSIS 
A systemic skeletal disease, osteoporosis is characterized by a decreased in the bone mineral 
density (BMD) as well as deterioration of its microarchitecture. It thus results in an increase in 
the fragility of bones and hence an increased susceptibility to fractures. 
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Dual energy absorptiometry (DXA) scan is the current gold standard to diagnose 
osteoporosis(24). With this technique a definite bone mineral density (BMD) is acquired by 
measuring the amount of mineral in the scanned area of bone in grams divided by the measured 
bone surface in square centimetres 
The BMD score of patients is then expressed as T score, which is calculated by measuring the 
standard deviations by which the patient’s BMD varies from the mean BMD of a young control 
population. The International Society for Clinical Densitometry advices measuring BMD both 
at the lumbar spine and the hip, WHO advocates the measurement of the same at the hip 
alone(25). Of all the measured locations, the lowest T-score is used for the diagnosis of 
osteoporosis. Therefore osteoporosis according to the WHO is defined based on the basis of T-
score(Table 3)(24). 
 
Table 3: World Health Organisation (WHO) classification of osteoporosis based on the T-
score 
Normal T-score ≥ -1 
Osteopenia -1 > T-score > -2.5 
Osteoporosis T-score ≤ -2.5 
Established osteoporosis T-score ≤ -2,5 and fragility fracture(s) 
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For a whole body DXA-scan the cut-off values for osteoporosis and osteopenia must be 
adjusted according to Boyanov in order to obtain a good sensitivity to specificity ratio(Table 
4)(26). 
 
Table 4 Classification of whole body bone mineral density according to Boyanov (26) 
Normal T-score > -0.90 
Osteopenia -0.90 < T-score < -2.35 
Osteoporosis T-score < -2.35 
  
 
Of the different aspect of the bone health, only the BMD is measured by DXA scan, however, 
as mentioned before, Osteoporosis is characterized by not only a decrease in the mineral density 
of bones but also by a deterioration its microarchitecture. It results in fragility fractures. A 
DXA-scan measures only the mineral density of bones, but no way it can assess the deteriorated 
microarchitecture within. 
However an indirect way of assessing the same is a vertebral fracture in the past without a high 
energy trauma. According to Genant et al, by virtue of a morphometric method, vertebral 
deformities can be assessed on X-rays of the spine(27). Anterior, medial and posterior heights 
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of each vertebra are measured, following which comparisons are made amongst them and also 
to the heights of the vertebrae above and beneath that vertebra (Table 5)(28). 
  
Table 5 Morphometric method of vertebral fracture analysis 
Grading Radiological appearance 
 
Grade 1 
20-25% reduction in anterior, middle and/or posterior height  and 
10-20% reduction of the projected vertebral area 
Grade 2 25-40% reduction in height and 20-40% reduction of the projected 
vertebral area 
Grade 3 ≥40% reduction in height 
 
 
 
Fractures can also be classified according to their shape (Figure 3)(28).- 
o Wedge -reduction in anterior height 
o Biconcave -reduction in middle height 
o Crush -reduction in posterior height  
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Figure 3: Visual grading of the vertebral deformity and morphometric analysis(28)  
 
In a study conducted by Cummings et al patients with a normal bone mineral density as 
determined by DXA-scan did have vertebral fractures, thus supporting the fact that osteoporosis 
can be due to a deterioration in the bone microarchitecture even in the presence of a normal 
bone mineral density(29). 
Epidemiology and impact of osteoporosis: 
According to the World Health Organisation (WHO) a population of more than 75 million 
people in Europe, Japan and the USA is affected with osteoporosis(24). In fact, the lifetime risk 
for osteoporotic fractures has been estimated to be near about 40%, which is similar to that for 
coronary heart disease. To make matter worse, osteoporosis also causes loss of height, back pain 
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and decreased quality of life.  Moreover, a fracture increases the mortality e.g. the risk of death 
is increased over ten-fold in the first seven days following a fracture(30). 
Aetiology of osteoporosis 
Multiple aetiological factors have been identified. Risk factors for osteoporosis as well as 
osteoporotic fractures include increased  
o Advanced age,  
o Lower body mass index,   
o smoking, 
o Greater than three units of alcohol per day, 
o Previous fracture before 50 years of age,  
o Parent with a fracture,  
o Immobility, 
o Systemic glucocorticoid usage and  
o Systemic connective tissue disorder.  
Pathology of osteoporosis 
Bone remodelling is a dynamic process. It is initiated on the surface of the bone. Lining cells on 
the bone surface respond to both local as well as systemic cytokines and hormones. 
Remodelling of a bone is the result of the coordinated activity of osteoclastic bone resorption 
and osteoblastic bone formation. Differentiation of osteoclasts is stimulated in interaction with 
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osteoblastic cells. This interaction involves binding of the receptor activator of nuclear factor 
kappa β (RANK) on osteoclasts to its ligand (RANKL) expressed by the osteoblast cells (Figure 
4)(31). 
 
Figure 4: Important steps in osteoporosis in COPD (RANK- receptor activator of nuclear 
factor kappa, RANKL-RANK ligand, OPD-Osteoprotegerin, PTH-Parathormone)(31). 
  
This binding of RANK to RANKL promotes both the differentiation as well as activity of 
osteoclasts. The tumor necrosis factor Receptor-Associated Factor (TRAF) adaptor proteins 
play an important role in the initial event of RANK induced signal transduction pathway. Most 
likely TRAF proteins act by transmitting the RANK induced signal to downstream targets 
(which includes nuclear factor kappa β). Osteoprotegerin (OPG) is secreted by osteoblasts; it 
acts as a natural decoy receptor. OPG binds to RANKL and thus inhibits the binding of RANK 
to RANKL. Thus OPG prevents bone loss in case of postmenopausal osteoporosis.  The Wnt 
signalling pathway (Wnt stands for Wingless-related integration site) also plays an important 
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role in the formation of bones by activating osteoblasts and inhibiting the osteoclast for bone 
resorption. This happens through series of activation of cascade proteins and transcription 
factors (Figure 5)(32). 
 
Figure 5 Wnt signalling increases bone formation and decreases resorption. It suppresses 
osteoporosis by osteoprotegerin and β catenin mediated pathways and increases bone 
formation through Dkk-1 and sclerostin mediated pathway. (LRP, LDL receptor related 
protein co-receptor, Dkk-1, Dickkopf-related protein 1)(32). 
 
Wherever there is increased bone remodelling, there is an increase in the risk of fracture and this 
is due to multiple factors- the primary reason being a decrease in the stiffness of the bones.  This 
is reduced because a bone which was once more densely mineralized gets replaced with less 
densely mineralised younger bone. Bone remodelling also increases the fragility of bone and 
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this happens because of impairment in the maturation of collagen due to an alteration in the 
cross linking between the adjacent collagen fibrils. Finally, the sites which undergo resorption 
remain temporarily naked, and thus predispose the bone to microdamage as a result of stress 
concentrators. Factors which increase bone remodelling include both calcium as well as vitamin 
D deficiency by virtue of secondary hyperparathyroidism. 
 
Osteoporosis and other chronic diseases: 
There are several chronic diseases involving a single or multiple systems that lead to secondary 
osteoporosis in the long run. In fact the prevalence of secondary osteoporosis has been found to 
be significantly high in those with inflammatory bowel disease, sarcoidosis and also COPD. 
Systemic inflammation is the common link amongst all these disease conditions. Indeed, it 
proves that chronic IBD cause production of cytokines which in turn stimulate bone turnover. 
This leads to an increase in bone fragility and hence an increased risk of fracture. Indeed, Bon 
and his colleagues found a correlation between the C-telopeptides of type I collagen (which is a 
marker of bone resorption) and interleukine-4 as well as tumor necrosis factor α in COPD 
patients which was significant(33). Moreover, they also found a significant correlation between 
the N-terminal procollagen propeptide (again a marker of bone formation) and both IL- 4 as 
well as TNF-α. Another link between these diseases and osteoporosis could be physical 
inactivity, which in turn leads to a low BMD. Also certain risk factors for osteoporosis and 
some chronic diseases are similar e.g. smoking. However, pathogenesis of osteoporosis in these 
chronic diseases is very complicated & not fully understood yet. 
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OSTEOPOROSIS AND COPD: 
GLOBAL: 
 
Osteoporosis is highly prevalent among patients with COPD. In fact it is estimated to be a 
whopping 2 to 5 times higher in those with COPD in comparison to healthy subjects(34). Study 
done by Graat et al showed that in developed nations the prevalence of osteoporosis in patients 
with COPD is somewhere in between 4% and 59%(35). Differences in the study population, 
diagnostics methods as well as difference in the severity of the underlying disease in the studied 
population lead to this highly wide range. In the past increased prevalence of osteoporosis in 
COPD patients was solely attributed to the use of corticosteroids. However, it was also seen that 
corticosteroid naive COPD patients also had a high prevalence of osteoporosis among them, and 
hence it suggests a more complex mechanism underneath(36).  Measures of a low body 
composition and measures of disease severity are the correlates of osteoporosis in COPD. 
Prevalence of vertebral compression fracture in those with COPD has been explored by multiple 
studies and it was reported to vary from 24% to 63%. The prevalence of hip fracture in COPD 
patients has not been studied in details yet. However a study done by Walsh et al has shown that 
there is an increase in the prevalence of hip fracture in those with miscellaneous lung conditions 
out of which around 52% were diagnosed with COPD(37). 
However most of these studies used only DXA in order to assess osteoporosis. Morover, most 
of them were cross sectional. Given the fact that fractures of the hip pose an increased operative 
risk in those with COPD as compared to healthy subject, the prevention of osteoporotic as well 
as vertebral fractures becomes all the more important in COPD patients(38). To add to all 
worries, a vertebral fracture might lead to a decrease in the forced vital capacity(39). Moreover, 
treating these fractures is itself very complicated with a lot of risks involved such as venous  
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thromboembolism and also peri-operative complication. Therefore, an early and efficient 
treatment of osteoporosis should be considered. This treatment should not only consist of 
pharmacological therapy but also lifestyle advises (for example weight baring physical exercise, 
cessation of smoking and the use of dairy products). The former should consist of 
bisphosphonates and calcium with/without vitamin D. However, to date, it is still not well 
known whether and also to what extend physicians prescribe any bone medications to COPD 
patients with osteoporosis. 
 
 
Risk factors for osteoporosis in those with COPD: 
Both COPD and osteoporosis are chronic conditions. Osteoporosis has been found to occur in a 
significant number of patients with COPD. However, it is not very clear whether the increase in 
the prevalence of osteoporosis in COPD patients as compared to healthy subjects is due to a 
common underlying pathophysiological mechanism or a consequence of multiple shared risk 
factors. Chronic diseases are also characterized by end organ damage. Such damage may be the 
result of continuous interaction of common (both modifiable and non-modifiable) as well as 
intermediate risk factors(40). COPD and osteoporosis have multiple common risk factors 
(Table 6). A detailed discussion of some of these risk factors can be found below- 
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Table 6 Risk factors for COPD and Osteoporosis 
Common risk factors  
Intermediate risk factors Modifiable Non-modifiable 
Nutrition Genetic Visceral fat 
Physical inactivity Gender Repair 
smoking Aging Vitamin D deficiency 
  Systemic inflammation 
 
Nutrition and body composition: 
A common risk factor for osteoporosis identified in general population is low BMI(41). As a 
consequence of low BMI there is reduced mechanical loading on the bones which in turn leads 
to a loss in the bone mass; as studied by Cavanagh et al and this was clearly evident among the 
astronauts(42). Indeed, in multiple studies a low BMI was found to be a common factor among 
COPD patients with osteoporosis.  
 
Research done both earlier as well as recently, strengthened the importance of body 
composition in the disease manifestation and prognosis of COPD. A lower than normal body 
weight has been found to be an independent risk predictor of mortality in those with COPD. 
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Reduced muscle mass, which is assessed by measuring fat free mass, is an even better predictor 
of mortality as compared to BMI in such patients. In addition, a low muscle mass has also been 
found to be associated with a poor health status in patients with COPD. Previous studies have 
reported a significantly high prevalence of fat free mass as well as low body weight in COPD 
patients; this ranges from 20% in clinically stable outpatients to a whopping 41% in those 
requiring pulmonary rehabilitation. In fact, one of the characteristic findings of cachexia is a 
low fat free mass. 
Besides malnutrition, cachexia is caused by an imbalance in protein breakdown and synthesis. A 
commonly used marker of protein breakdown is pseudouridine (PSU)(43). Protein breakdown 
can be easily assessed using PSU as it offer the advantage of not requiring any dietary 
limitations; also it is a suitable marker because once it is produced, it is neither metabolized 
further nor reused by the body. Indeed, in paediatric patients receiving growth hormone therapy, 
a significant negative correlation was shown between changes in PSU concentrations in urine 
and ornithine concentrations in plasma (which is a traditional marker of anabolism in tissues). 
The fact that protein imbalance can cause cachexia was shown by an increased pseudouridine in 
patients with a low fat free mass (FFM),  low fat free mass index (FFMI), and also impaired 
skeletal muscle function(34). Protein breakdown in these patients will not only cause a 
reduction in the muscle mass, but it will also induce a loss in bone tissue. Bolton and colleagues 
found in their study that those with a low FFMI had an increased PSU levels and also a lower 
BMD(44). This study also correlated a low FFMI to interleukin-6 (IL-6), thus indicating that 
systemic inflammation could possibly be the link between a low body composition and 
osteoporosis in patients with COPD. However, studies done by other researchers such as 
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Broekhuizen et al did not come across a significant correlation between body composition and 
systemic inflammation(45). 
Increased mechanical loading could be the reason as to why an overweight or obese COPD 
patient is protected from osteoporosis. Mechanical loading results in bone formation probably 
by stimulation of osteocytes that act as mechanosensors and thus respond to motion of the fluid 
in the lacunae and the canaliculi within a bone. This in turn leads to a positive balance within 
the bone remodelling cycle; and thus an increased BMD(46). 
Another factor that could be protective in overweight or obese patients could be leptin. A part of 
the cytokine family, leptin is produced primarily in the adipocytes and it circulates in the blood. 
Its blood levels are directly corresponds to the amount of body fat i.e. those with a higher 
adipose reserve have increased blood levels of leptin(47). Leptin functions by inhibiting appetite 
by virtue of its action on the receptors located in the hypothalamus. In addition, leptin promotes 
formation of bones by increasing the proliferation and also the differentiation of osteoblasts. It 
is believed that this effect of leptin could be enhanced in obese patients with COPD since 
circulating leptin levels were found to be higher in female COPD patients in comparison to 
healthy subjects matched for age and BMI(48).  
However a negative effect on bone metabolism has also been found. Therefore, it could be that 
leptin has a biphasic effect on bone: a lower serum levels promote increasing bone formation 
but suppresses bone formation at higher serum levels. In patients with COPD a significant 
positive link was established between BMD and serum leptin levels, however, such an effect 
was not independent of body mass(47). 
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Physical inactivity: 
COPD patients have been found to be physically less active in comparison to healthy subjects. 
These patients showed lower standing time, walking time and also significantly less movement 
intensity during walking(49). They also had higher lying time and sitting time. It was also found 
that approximately 30 to 50% COPD patients walked less than a mere 30 min every day, which 
is, in fact, the recommended minimum amount of regular physical exercise that is necessary to 
develop physical fitness. As expected the physical inactivity would be more in GOLD stage IV 
COPD than with stage I patients.  
 
The precise mechanism by which physical inactivity leads to osteoporosis is not very clear yet. 
Nevertheless, studies in both human and animal  have proved that disuse, especially if its long 
term,  leads to decrease in the BMD, disorder in the architecture of bones, a reduction in the 
bone mechanical properties; the consequence of all these is an increase in the incidence of bone 
fracture. Moreover, physical inactivity results in sarcopenia which may play a role in bone 
loss(50). In addition, weakness of muscles of the lower limbs exerts a significantly powerful 
influence on the incidence of hip fractures due to its effect on the risk of falls. Physical exercise, 
especially those involving weight bearing activity were found to have a positive effect on the 
BMD. Indeed, a decreased BMD was experienced by astronauts in weight-bearing bones. 
Further research is required to establish the dose-response relationships between bone strength 
and exercise and also the duration as well as the form of exercise. 
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Smoking and COPD: 
There is an increased risk of osteoporosis with smoking in the general population. Indeed, a 2-4 
fold increase in odds ratio for osteoporotic fractures was found in smokers compared to healthy 
non-smokers in multiple case control studies(51). However, it is not yet clear how smoking 
induces osteoporosis. Smokers usually have a lower body weight as compared to their non-
smoking peers; this reduced BMI could possibly be the reason behind the high prevalence of 
osteoporosis among smokers. Menopause occurs at an earlier age among women who smoke as 
compared to non-smoking healthy female subjects; the age at onset of menopause being a very 
strong predictor for osteoporosis. Also there seems to be an adverse effect of cigarette smoke on 
those hormones which are involved in the process of regulation of bone metabolism; example 
includes alkaline phosphatase and parathormone. However the underlying mechanism is not 
fully known but whatever the mechanism could be, smoking seems to have a dose effect which 
is clearly evident by virtue of the fact that the effect on bone mineral density in found in both 
male and female subjects of higher age having a long term history of smoking(52). 
Additionally, in young adults, smoking was found to exert a significant effect on bone mass in 
studies which included only the heavy smokers in the analysis. Also we know that the effect of 
cigarette smoking on the bone status is associated mainly with the duration and amount of 
smoking in the elderly population(51). It might also be that smoking causes a decrease in bone 
mass by bringing up an alteration in the blood levels of hormones produced from the adrenal 
cortex. 
A lower level of 25-hydroxyvitamin D has been found to exist in smokers in comparison with 
non-smokers in several studies; however the precise mechanism of this association is not yet. 
Enhanced metabolism of the metabolites of vitamin D in the liver as a result of induction of 
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hepatic enzymes by virtue of smoking has been suggested as a possible mechanism for a lower 
vitamin D levels in smokers as mentioned above(52). Impaired calcium absorption is another 
significant factor which enhances bone loss in individuals who smoke. The absorption of 
calcium was found to be lower in smokers in comparison to subjects who did not smoke after 
adjustment was made for age, gender, intake of calcium supplements as well as dietary calcium 
and vitamin D intake, especially in those individuals who had smoked >20 cigarettes/day(47). 
Finally, smoking exerts a significantly more deleterious effect on the bone mass in men when 
compared to women; also men have greater tobacco intake than women (Figure 6). However, on 
the other hand, in women, the reduced influence of cigarette smoking on the bone mass may be 
due to the interference of either oral contraceptive metabolism or because of oestrogen 
replacement. In addition very little data is available on the possible association that smoking, 
duration, length of time after cessation, type of tobacco and fracture risk. 
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Figure 6 Effect of smoking on various aspects of the bone health (SHBG- sex hormone 
binding globulin) 
 
The exact molecular mechanism underlying this effect of smoking on bone mass has not been 
studied extensively yet. In vitro studies have demonstrated a decrease in the proliferation and 
impairment in the synthesis of collagen in osteoblast-like cells which were exposed to high 
concentrations of nicotine as well as the non-nicotine constituents of found in cigarette smoke. 
One of the studies used a bone graft revascularization rabbit model to show this effect(53). The 
authors implanted a cancellous bone graft into the distal femur of the experimental specimen 
and demonstrated impaired vascularization of the implant in presence of elevated levels of 
nicotine in the system. Other authors have been successful in demonstration of osteoblasts death 
as a result of direct harmful and toxic effects of smoking(51). 
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Systemic inflammation: 
The prevalence of osteoporosis is high in various systemic inflammatory conditions, common 
examples being inflammatory bowel disease, (rheumatoid) arthritis and sarcoidosis(54). This 
serves as an indirect indicator that the development of osteoporosis maybe caused or accelerated 
by the presence of systemic inflammation. As a matter of fact, numerous studies have 
conclusively proven that even with a small increase in the level of any systemic inflammation, 
there can be substantial precipitation of bone loss in an individual(55). Indeed, it can emerge as 
a strong and independent risk factor for occurrence of osteoporotic fractures.  
 
Chronic inflammatory conditions activate the immune system which in turn leads to the 
synthesis of molecules which exert a negative effect on the process of bone homeostasis. A 
significant feature that is associated with inflammatory bone loss is enhanced osteoclastogenesis 
and hence increased bone resorption; however in inflammatory diseases the formation of bones 
is blunted rather than being enhanced. In the process of inflammatory bone loss, there is an 
increase in the recruitment of precursors of osteoclasts from within the bone marrow and thus 
osteoclastogenesis is enhanced. Once the precursor cells are recruited, the osteoclasts undergo 
differentiation from their precursor cells. This process is mediated by prostaglandin and 
cytokines.  
 
The mechanism underlying suppression of bone formation is in chronic inflammatory diseases 
is not clear yet. However, with the little data that we have, it has been shown that proteins such 
as Dickopf 1 and sclerosin are induced by tumor necrosis factor α (TNF- α)(56). These proteins 
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are potent inhibitors of the Wnt pathway and thus they can blunt bone formation leading to 
symptoms of osteoporosis and its sequelae. In COPD patients there is evidence of existence of a 
chronic low grade inflammation in the system. We should also note that this systemic 
inflammation is very heterogeneous, which is evident due to different levels of increased acute 
phase proteins, cytokines and other circulating cells that were identified in numerous studies.  
 
A cross sectional study which including 409 patients with COPD and 231 healthy subjects 
without COPD, showed an independent rise of C-reactive protein (CRP) as well as monocyte 
chemo attractant protein (MCP)-4 in male patients with COPD. Several chemo-attractants and 
cytokines were found to be increased in patients with COPD in a study conducted among 48 
COPD patients who were compared to a set of 48 matched controls(57). A few of these 
biomarkers were IL-15, interferon gamma, TNF-α and IL-17. As discussed earlier, in 
inflammatory diseases, the expression of RANKL is exaggerated by cytokines. In the Bergen 
cohort study, in COPD patients the level of OPG was found to be dysregulated. 
 
A significantly lower level of OPG was found in COPD patients when compared to healthy 
subjects without COPD; surprisingly a higher plasma OPG level was associated with a low 
FEV1 and also COPD exacerbations in previous years. Bon and colleagues studied 40 COPD 
patients who required lung transplantation; they discovered that there exists a direct correlation 
between markers of systemic inflammation i.e. IL-4 and TNF-α and that of bone metabolism 
that include N-terminal procollagen propeptide (PINP) and C-telopeptides of type I collagen 
(CTx)(33). However unfortunately, in the cohort study by Bergen, the bone status of the 
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subjects was not assessed and in the study by Bon et al OPG levels weren't measured(46). 
Therefore, the possible correlation between inflammation, the bone status and the 
OPG/RANK/RANKL system in those with COPD is not proven yet. 
 
The Wnt-signaling pathway is influenced by inflammatory cytokines as shown in those with 
artrithis. Recently, a decreased Wnt/β-catenin signaling was shown to be involved in destruction 
of the lung parenchyma and it also leads to an impairment of the repair mechanisms in 
emphysema. Wnt-signaling plays a significant role in formation of bones by activating 
osteoblasts(32). Thus, the role of this Wnt-pathway on osteoporosis in COPD patients warrants 
further investigation. 
Vitamin D deficiency and osteoporosis in COPD: 
A varied prevalence of vitamin D deficiency was found among patients with COPD. Numerous 
studies have been undertaken and this prevalence was found to be somewhere in between 32 to 
51%(58). Vitamin D was found to be an independent risk factor for osteoporosis in number of 
prospective studies. Moreover, an increase in the PTH levels by virtue of secondary 
hyperparathyroidism in turn increased the odds ratio for osteoporosis. Additionally, apart from 
the effects of vitamin D on bone, non-calcemic effects of the same are described(59). Beside the 
kidneys, other tissues where 1-α-hydroxylase can be found are the skin, bone and also in 
immune cells. In these extra renal tissues the expression of 1-α-hydroxylase is regulated by 
immune signals (instead of mediators of calcium & bone homeostasis). High concentration of 
local 1,25-hydroxyvitamin D have autocrine as well as paracrine functions. Moreover, 1,25-
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hydroxyvitamin D also controls genes that are involved in the regulation of cellular 
differentiation, proliferation and apoptosis. 
Finally, 1,25-hydroxyvitamin D is also an immune modulator and therefore it stimulates the 
immune response to an infection. Indeed, vitamin D deficiency has been found to be associated 
in many diseases like malignancy, type I diabetes, rheumatoid arthritis, the metabolic syndrome, 
congestive heart failure and tuberculosis. Examples of non-calcemic effects of vitamin D 
deficiency in COPD patients are inflammation and muscular dysfunction.  In summary, vitamin 
D deficiency has both calcemic and non-calcemic effects(59).  
Exogenous hormonal factors: 
It is a well-known fact that the regular use of corticosteroids significantly increased the risk of 
osteoporosis. This is a result of uncoupling of bone formation as well as resorption. Inhaled 
corticosteroids were also found to have a dose related adrenal suppression which is a very well 
known risk factor for development of osteoporosis. However, studies done to assess the effects 
of inhaled corticosteroids on bone have several conflicting results. Gerald and colleagues 
conducted a meta-analysis and showed that inhaled corticosteroids did have a toxic effect on the 
markers of bone turnover as well as BMD in patients with COPD or asthma(60). As shown in 
TOwards A Revolution of COPD Health Study (TORCH) significant effect of inhaled 
corticosteroids was seen as compared to the placebo on the metabolism of bones in COPD  
patients who have been followed up for atleast 3 years now(61). 
 Its been found that there is an increased prevalence of apoptosis of osteocytes and a fewer no of 
osteoblasts in patients diagnosed to have oral corticosteroid induced secondary osteoporosis in 
comparison to healthy subjects. This apoptosis of the osteocytes is associated with a decrease in 
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the skeletal angiogenesis, bone strength and bone interstitial fluid possibly causing a loss of 
bone strength in those with corticosteroid-induced osteoporosis which usually occurs before the 
loss of BMD. Indeed, COPD patients who were also using oral corticosteroids were at a higher 
risk of fracture(55). Despite the fact that the use of oral corticosteroids in COPD patients is not 
recommended, they are often prescribed in stable COPD.  
INDIAN 
There was only one study that was published prior to the onset of this (BOAD study) which 
examined the problem of bone loss in COPD patients. Bhattacharya et al studied numerous 
patients with COPD commercially available ultrasound bone densitometer (HOLOGIC 
SAHARA)(62). Frequency of both osteoporosis and osteopenia was found to be high (73%).  
There was one more study which was published during the process of this dissertation which 
showed similar results(63). 
TAMILNADU 
There was no published data to our knowledge regarding prevalence of osteoporosis in COPD 
patient in Tamilnadu 
JUSTIFICATION 
At the outset, as mentioned above at the beginning of this study there was only study published 
regarding the prevalence of Osteoporosis in India. There was certain limitation of this study(62)  
1. Use of a technique which was no yet standardised. A meta-analysis of 25 studies that 
evaluated the sensitivity and specificity of calcaneal ultrasound for identifying patients 
with DXA T-scores ≤-2.5 concluded that currently used ultrasound cutoff thresholds do 
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not have sufficiently high sensitivity or specificity to definitively exclude or confirm 
DXA-diagnosed osteoporosis 
 
2. Another major limitation to using quantitative ultrasound as a screening tool is that the 
criteria for diagnosing osteoporosis and recommending treatment based upon ultrasound 
are not yet well established 
 
3. Ultrasound cannot reliably be used to follow patients who are treated for osteoporosis 
because of limited precision and a slow rate of change of bone mass at peripheral sites. 
 
There was another study that was published from Karnataka by Hattiholi et al(63), assessing the 
prevalence of osteoporosis. This study showed around 80% of patient with COPD has 
osteoporosis and Osteopenia. This was did not assess the other aspect of bone health like daily 
calcium intake and sunlight exposure. It also did not take into account the andropause induced 
decreased bone mass.  And it was published after the completion of the present dissertation 
In view of these issues, this study was designed to provide data to help answer the queries raised 
above. Lab parameters were also checked to look for any possible correlations and to rule our 
confounders. The result of this study will help to follow up the patient and treat early to prevent 
osteoporotic fracture.  
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MATERIALS AND METHODS 
Study type:  
It’s an Analytical study done at Christian Medical College, Vellore, Tamilnadu. 
STUDY DESIGN: 
It was designed as an observational study with a cross-sectional design.  
It involved observation of patient with Chronic Obstructive Pulmonary disease  
Data were obtained and recorded. 
Analysis of the obtained date was done subsequently 
There was no therapeutic intervention planned as part of this study.  
SETTING:  
The study was conducted among the patients visiting the outpatient services of Department of 
Pulmonary Medicine, Christian Medical College Hospital, Vellore.  
The details of recruitment of patients is presented in the flow chart below 
It was conducted under the auspices of the  
 Departments of General Medicine, 
  Department of  Endocrinology, Diabetes and Metabolism, 
 Department of Pulmonary Medicine and  
 Department of Clinical Biochemistry, Christian Medical College. 
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DURATION OF THE STUDY:  
The study was conducted between September 2012 and June 2014.  
The recruitment phase spanned a period from December 2012 to March 2014.  
INCLUSION CRITERIA 
 Male patient diagnosed  to have COPD as per GOLD COPD criteria 
o Female patient not included to reduce the confounding effect of post-
menopausal osteoporosis. 
 Age 40-70 years old 
o This age group is chosen to maintain uniformity in age in study 
population as COPD as well as osteoporosis become more common as 
age advances 
 Patient residing in Tamil Nadu  
o This criterion is applied to maintain uniformity in ethnicity and dietary 
pattern in study population 
 No localized lesion on chest X-ray 
o To avoid pulmonary function test abnormalities caused by respiratory 
diseases other than COPD 
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EXCLUSION CRITERIA 
 Patient on diuretics  
o As these patients are likely to have electrolyte imbalance. Also patients 
on diuretics may be unwell to complete the evaluation.   
 Patients requiring Oxygen supplementation  
o As these patients will unwell to complete the evaluation.   
 Renal failure 
o It will be difficult to interpret the result because of pre-existing metabolic 
bone disease 
 Liver failure (For similar reasons as mentioned above) 
 Patient on bone medication like calcium, Vitamin D and Bisphosphonates  
o As these drugs will modify the bone health 
 Mentally disabled persons  
o Who will be unable to give a valid consent 
 History or being treated for cancer  
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o As some cancer will influence bone health 
 Patient diagnosed or being treated for HIV infection  
As the diseases per se and the medication used to treat alters the bone health 
SAMPLE SIZE 
The sample size was calculated using prevalence data from previous studies conducted in and 
round the country and outside the country(62,63).  The calculation was based on the 
assumption that similar prevalence would be present in our study. 
As referenced previously the prevalence of low bone mineral density (osteoporosis and 
osteopenia) widely varies between the populations studied.  With the prevalence of Low BMD 
of 73-80% as shown among patient with COPD by Bhattacharyya et al was taken for the sample 
size calculation(62). 
The following calculation (P=Prevalence of low bone density as 80%) yielded the sample size 
of 64 for this study. 
n= 4*p*q 
                                                          d2 
  
 Where:  
          n is the sample size, 
          q= 100-p= 20 
          d= precision= + 10%  
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PATIENT RECRUITMENT: 
Consecutive patients visiting pulmonary medicine outpatient services of Christian Medical 
College Hospital, Vellore were screened and patient with or newly diagnosed to have COPD as 
per the GOLD criteria were enrolled in to the study if they meet the inclusion and exclusion 
criteria 
 
All included enrolled patients were provided with the study details in the form of patient 
information sheet in the language they understand and was explained by the Principal 
investigator after which a written consent was obtained (Annexure.) 
The following information were collected with the tools as given below 
 
CLINICAL ASSESSMENT AND ANTHROPOMETRY 
The qualitative variables like history of COPD and other diseases and their treatment and that 
associated with the various facets of lifestyle including, nutritional, physical activity were 
ascertained using a standardized questionnaire. A detailed history regarding current and past 
medications for management of COPD (including oral and inhaled steroids, their dose and 
duration) as well as pre-existing co-morbidities (eg. Diabetes, hypertension, dyslipidemia) was 
obtained.  
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Weight – Weight was measured by an electronic weighing machine by asking the patient to 
stand steady for 10 seconds on the platform.  
 
Height – Height was measured from the highest point of vertex to the ground level by 
standardized measuring tape when the patient is standing on an even ground with his occiput, 
buttocks and heels touching the wall.  
 
Waist circumference - As per the expert committee y WHO, Waist circumference was measured 
at the approximate midpoint between the lower margin of the last palpable rib and the top of the 
iliac crest.  
 
Waist-Hip ration - Waist-Hip ration was calculated by dividing waist circumference by 
measurement around the widest portion of the buttocks.  
 
Dietary calcium intake- Dietary calcium intake was calculated by the 24 hours dietary recalled 
method and sunlight exposure was calculated form duration the patients are exposed to the 
sunlight when the shadow formed due to sunlight is larger than the real image. 
. 
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LUNG FUNCTION TEST 
 
Spirometry - Spirometry was performed by Respiratory Therapist by Jaeger spirometer as per 
American Thoracic Society Guidelines. Patients were classified according to the severity as per 
the GOLD criteria (Table 1). 
Six minute walk test was performed to calculate the distance covered (in meters) in 6 minutes as 
per the American Thoracic Society Guidelines 
Furthermore BODE Index was calculated for all the patients to assess severity. The BODE 
Index is a composite marker of disease taking into consideration the systemic nature of COPD 
(Table 7). 
 
Table 7 BODE severity index (FEV1% predicted defined as a percentage of the forced 
expiratory lung volume in one second; 6MWD = six minute walking distance; MMRC = 
modified medical research council dyspnea scale; BMI = body mass index) 
Parameter/Points 0 1 2 3 
BMI >21 ≤21 — — 
FEV1 (% predicted) ≥65% 50–64% 36–49% ≤35% 
MMRC score 0-1 2 3 4 
6 MWT(meters) ≥350 250–349 150–249 ≤149 
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LABORATORY ASSESSMENT 
Fasting blood samples will be collected for the assessment of the following analyses (reference 
normal ranges in our laboratory shown parenthetically):  
 Serum calcium (8.3 to 10.4 mg/dL), 
 Serum phosphorus (2.5 to 4.6 mg/dL),  
 Serum alkaline phosphatase (40 to 125 U/L),  
 Serum albumin (3.5 to 5.0 g/dL),  
 Serum creatinine (0.5 to 1.4 mg/dL),  
 Serum 25-hydroxyvitamin D [25(OH)D] (normal 30 ng/mL or greater),  
 Serum intact parathyroid hormone (iPTH) (8 to 50 pg/mL),  
 Serum total testosterone (300 to 1,030 ng/dL), and  
 Serum Cortisol measured at 8 am.  
 
The biochemical variables were measured by microanalyzer manufactured by Hitachi model 
911. The intra-assay and interassay coefficients of variation of the variables being studied from 
these machines were 1% to 5%. A radioimmunoassay manufactured by DiaSorin, Stillwater, 
was used to estimate of 25-OH vitamin D levels. The intra-assay coefficient of variation was 
5.5% and 9.3% at a 25(OH)D level of 15.6 ng/mL and 52.5 ng/mL. iPTH respectively. The 
serum testosterone was measured by chemiluminescence by Immulite 2000 analyzer. 
Assessment of BMD was perfomred by using the Hologic machine (QDR 4500; Hologic) at the 
lumbar spine (L1 to L4), forearm, femoral head and the femoral neck. The reference population 
consisted of normal white subjects  used by the manufacturer’s database. The precision was 2%. 
The World Health Organization criteria for osteoporosis was used for analysis. 
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STATISTICAL ANALYSIS:  
The data collected was entered in Excel spread sheet (annexure).  Continuous variables were 
described using means and standard deviations, if normally distributed. For variables with 
skewed distributions medians with interquartile ranges were used to summarize the distribution.  
All categorical variables were summarized by using frequencies and percentages. Logistic 
regression model was constructed in order to assess the relationship between parameters 
showing positive trend with osteoporosis in COPD.  All statistical analyses were done using 
SPSS version 11 software (SPSS, Inc., Chicago, Illinois). 
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STROBE STATEMENT  
 
 
 
 
 
All the 67 patients were included for the analysis 
All the patient underwent focussed history and examination
Parameters related to bone health - Blood investigations and 
DXA were measured
After fulfilling the inclusion and exclusion criteria
67 patient were included in the study 
Stable male COPD patient in the age group 40-70 years
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RESULTS 
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BASE LINE CHARACTERISTICS: 
The baseline characteristics of the 67 patient after enrolled into the study after full filling the 
inclusion and exclusion criteria are as follows (Table 8). 
Table 8 Baseline characteristics of the study population 
Parameter Mean ±SD 
1. Age (years) 60±6 years 
2. Duration of COPD (Months) Median-  60 (Range-  6-354) 
3. Smoking  status (number)  
a. Never smoked      7 
b. Current smoker   7 
c. Ex-smoker   53 
4. Smoking pack-years   Median – 30 (Range- 5-120) 
5. FEV1 (% of predicted)   42.25±18 
6. FVC   61.37±17 
7. FEV1/FVC   67.67 ± 17 
8. GOLD staging ( number)  
a. Stage I   1 
b. Stage II   18 
c. Stage III   25 
d. Stage IV   23 
9. 6 MWT distance (meters)   347.97 
10. BODE index    
11. Oral steroid use   
a. Dose (mg)  10mg – 40 mg(Range) 
b. Duration (days) Median- 7 (Range5-120) 
12. History of Diabetes(number) 15 
13. History of Hypertension (number) 10 
14. Dyslipidemia  15 
15.  Sunlight exposure(<30 minutes) 9 
16. Dietary calcium intake(<1000mg/day) 26 
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Age category: 
The patients recruited were between the ages 40 to 70 years with the median of 60±6 years. The 
lowest age was 50 years and the highest was 70 years.  The age distribution for each decade is 
shown in the (Figure 7) 
 
Figure 7 Age distribution of the patients included in the study.  
 
When divided into two categories for above and below 60 years, there were almost equal 
numbers of patient above and below 60 years. This division was done to understand the risk of 
osteoporosis as the age advances. The prevalence was more in advanced age group as compared 
to the younger age group. This is because of the number of hormonal and non-hormonal 
mechanism that comes into play with advancing age. 
 
46%(36)
54%(31)
<60 years >60 years
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Duration of COPD  
The mean duration of COPD of the patient enrolled in the study is 62 months and the median is 
48 months and the range is between 2months to 360 months. The patients were divided in to 
four categories based on the duration for further analysis (Figure 8).  
o Category 1- less than 12 months , n=10 patients 
o Category 2- 12 months to 60 months, n=35 patients 
o Category 3- 60 months to 120 months, n=22 patients 
o Category 4-more than 120  months, n=4 patients 
 
 
Figure 8 Error bar plot showing the duration of COPD of the study population. (Category 
1, 2, 3 and 4 implies duration disease < 12 months, 12 to 60 months, 60 to 120 months and 
more than 120 months respectively) 
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GOLD stage of COPD 
The majority of the patients were distributed equally in the Stage II, III and IV. There was only 
one patient in stage I disease (Figure 9). 
 
Figure 9 GOLD COPD staging of the patient. There were equal numbers of patients in all 
the stages except in stage I which represent the mild disease 
COPD is classified into four stages from Stage I to IV ( ). Stage I disease is being mild Table 1
and stage IV being severe. This division is based on the spirometry value and not based on the 
patient symptoms or day to day activities except in the stage IV disease. Hence this system of 
division of patient purely on the basis of spirometry value was criticized.  This problem can be 
overcome by using the BODE severity index. 
 
2%(1)
27%(18)
37%(25)
34%(23)
COPD GOLD staging of the study patient
STAGE I STAGE II STAGE III STAGE IV
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SEVERITY OF PULMONARY FUNCTION TEST: 
All patients underwent spirometry testing if there was no lung function testing done in the last 
one year. The spirometry values for FEV1 and FEV1/FVC were studies and was plotted  
FEV1 trend 
The trend across the FEV1 values were studied and plotted. Patient in COPD have progressively 
declining FEV1 as the disease advances 
 
 
Figure 10 FEV1 Histogram showing the trends across the entire patient (FEV1-Post 
dilator Forced expiratory volume at 1st minute, FVC- forced vital capacity). 
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The mean FEV1 of the study population was 42.25% with standard deviation of 18.63 (Figure 
10). In the above histogram the FEV1 values very tend to cluster in the 30% to 60 % range 
indicating moderate severity of the disease population in this study population. 
FEV1/FVC ratio: 
 
 
Figure 11: FEV1/FVC histogram showing the trends across the entire patient (FEV1-Post 
dilator Forced expiratory volume at 1st minute, FVC- forced vital capacity). 
The FEV1/FVC ratio showed the similar trend as compared to FEV1. There was one patient in 
stage I disease. The mean FEV1/FVC ratio was 67.7 with standard deviation of 17.4 (Figure 
11). Although spirometry is used for diagnosis of COPD, but in Stage I disease where the 
FEV1/FVC 
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FEV1/FVC ratio is near normal. Hence stage I disease is mainly diagnosed clinically in patients 
who has risk factor for the disease with clinical signs for the same.  
Six minute walk test 
All patients also underwent six minute walk test. The six minute walk test is the quantitative 
method for assessing the severity of COPD with respect to restriction to the day today activities. 
The more the distance walked with normal saturation the less severe is the disease. The vice 
versa is true. And also used for follow up.    
 
 
Figure 12: The histogram shows the trend among the study patient in the six minute walk 
test 
Distance walked in meters 
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The mean and median distance walked is shown in the histogram (Figure 12).  Most of the 
patient covered only moderate walking distance. This is the quantitative way of estimating the 
disease activity restricting the patient activities of the daily living. 
Modified medical research council (MMRC) scale: 
Each and every patient in this study underwent qualitative and quantitative dyspnoea 
assessment. The dyspnoea assessment that we used was the MMRC scale which has been 
previously validated. 
 
Figure 13: MMRC dyspnoea scale of the patient enrolled in the study. MMRC- Modified 
medical research council. 
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Most of the patients enrolled in our study belong to the moderate dyspnoea score ( Figure 13). 
This is expected as the patients were all enrolled from the outpatient services. The sick patient 
with high MMRC score are generally admitted for further management. 
BODE index 
The BODE index was calculated for all patients.  BODE index was grouped in to three 
categories. 
o Less than 5 
o Between 5 to 7 
o More than 7 
 This categories is based on the previous studies relating BODE index to mortality risk at two 
years. 
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Figure 14: Histogram of the overall BODE score of the patient enrolled in the study 
(BODE stands for Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise) 
 
 
 
Most of the patients were in the moderate severity (Figure 14). This score takes into account 
both the clinical parameters and the spirometry value. Hence it predicts the disease severity to 
greater accuracy than compared to the GOLD staging alone. 
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The frequency of patient in each category is as follows less than 5, 5 -7 and more 7 is 8, 7 and 
52 patients respectively (Figure 15) 
 
 
 
Figure 15: BODE index categorisation. The categories were based on mortality risk. The 
less than 5 have least mortality risk compared with more than 7. (BODE stands for Body-
Mass Index, Airflow Obstruction, Dyspnea, and Exercise. BODE_CAT –BODE 
categorisation). 
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The mortality risk according to BODE index in each category is as follows 
– greater than 7 is associated with a 30 percent 2-year mortality 
– Score of 5 to 7 is associated with 15 percent 2-year mortality.  
– less than 5, the 2-year mortality is less than 10 percent 
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Treatment characteristics: 
Inhaled steroid: 
All of them received inhaled steroids. The inhaled steroids were calculated for Budesonide 
equivalent dose.  They were group into low dose and high dose category based on the daily 
cumulative steroid dose inhaled. The low dose category received daily cumulative dose of 
budesonide < 800 ug/day and high dose category received more than 800 ug/day. This 
classification is based on the TORCH trial which showed high dose patients are more prone for 
osteoporosis(64). 
 
Figure 16: Daily cumulative dose of inhaled steroids (Budesonide equivalent) of the patient 
in the study 
Only less than 10% of the patient received high dose steroids (Figure 16). This is accordance 
with the study population, as these  are stable COPD patients whose disease are near optimally 
controlled. 
86%(58)
14%(9)
LOW DOSE(< 800)
HIGH DOSE(>800)
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Oral steroid 
There were seven patients who received oral steroids in the last two years. The dose ranges from 
5 to 120 days (Figure 17). These patients were in the stage III and IV disease and had high 
BODE index score. 
 
Figure 17: Percentage of the patient who took oral steroid during the study period 
The oral steroids were calculated for prednisolone equivalent dose. Most of the patients’ disease 
activity was controlled only with inhaled steroids. Only very patients had taken oral steroids. 
 
 
 
 
 
22%
78%
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Smoking status  
The smoking status of the patient included in the study is as follows. There were 7 patients who 
were still current smokers (Figure 18) 
 
Figure 18: Smoking status of the population enrolled into the study 
 
Of the 67 people recruited for the study, 7 patients were never smokers. Of the remaining 60 
patients, 7 were current smokers. There were 40 patients who had significant smoking history of 
more than 20 pack years and 20 patients had less than 20 pack years of smoking (Figure 19). 
90%(60)
10%(7)
Smoking status
Non current smoker current smoker
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Figure 19:  Duration of smoking of the study population 
 
 
As expected most of the patient where in the more than 20 pack years category indicating that 
one of the main risk factors for the development of the COPD in the first place was significant 
active or passive smoking. 
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Co-morbidity  
The patients were assessed for the presence or absence of other co-morbidities like Diabetes 
mellitus, systemic hypertension and dyslipidaemia.  And the presence of this co-morbidities and 
the influence of the bone health is correlated later in the analysis 
 
Figure 20: Presence of co-morbidities in the study population 
 
There were 22(32%) in this study who had atleast one comorbidity (Figure 20). This again 
emphasising the point that patient with COPD have increased risk of systemic side effects either 
due to disease or due to treatment or both.   
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Andropause 
The bone health is greatly influenced by the endogenous gonadal hormone. This relation is 
greater in women than compared with men. This is one of the reasons why all men were 
included in this study to rule out the effect of endogenous hormones. But even in men as 
explained previously there is significant contribution to decrease in bone mass by the declining 
testosterone level in the age more than 50 years. All patients were asked about the sexual history 
and the serum testosterone level was also measured (Figure 21). This is was done primarily to 
rule out any significant influence of andropause on the bone health of these patient 
 
Figure 21: Comparison of the testosterone level with loss of libido 
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There was set of patient in our study who had low total serum testosterone level but had normal 
sexual function. This could be possible due to multiple reasons –normal free testosterone level, 
diurnal variation in the level of hormones and COPD affect the hormonal production but the 
receptor sensitivity to these hormones were increased. 
 
Sunlight exposure and dietary calcium intake  
The daily sunlight exposure was calculated as per method explained in the methods section and 
the 24 hour dietary recall method used to assess the dietary calcium intake. The daily 
recommended calcium intake is 1000mg per day. 
 
The sunlight is one of the intermediate variables contributing the bone health of the patient with 
COPD. A decrease in sunlight exposure will result in decreased synthesis of vitamin D which 
has hormonal and extra-hormonal like action on the bone. The recommended duration of 
sunlight exposure from the previous studies were atleast 30 minutes per day such that the 
shadow formed due to the sunlight is more than the real size object. This is the early noon and 
late noon sunlight which has highest concentration of Ultraviolet B rays for Vitamin D 
synthesis.  
 
The duration of the sunlight exposure recommended was more than 30 minutes per days. In 
COPD patients this may be restricted because of the restriction of outdoor activity due to 
dyspnoea, body composition and in the late stage due to the requirement of the oxygen.  
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Figure 22: The sunlight exposure of the study population 
 
Only less than 20 patients in our study had adequate sunlight exposure (Figure 22). This may be 
due to lot of reason. The restriction of outdoor activities as explained above. The dressing trends 
of the people in south India.  The advanced age group of the patients enrolled in the study who 
generally carries covering like umbrella to cover from the sunlight when they go out to the sun.  
The importance of the intake of the raw material for bone turnover was well emphasized in the 
discussion. The RDA (recommended daily allowance) for calcium intake for the Indians is 
1000mg per day. The study population were classified into low and high calcium intake groups 
based on this cut off (Figure 23) 
13%
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Figure 23:  Dietary calcium intake of the study population 
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Anthropometric measures 
The following table gives the important anthropometric measures of the population studied and 
their mean, median, standard deviation and range (Table 9). 
Table 9 Anthropometric measures of the patient BMI- Body mass index, Hip-Hip 
circumference, WHR weight hip ration.  
    Height 
cm 
Weight 
kgs 
BMI 
Kg/m2 
Waist 
cm 
Hip 
cm 
WHR 
Mean 163.13 61.29 23.00 88.23 89.50 0.98 
Median 163 60 22.96 89 89 97.56 
Std. Deviation 6.55 14.21 5.05 13.84 12.80 6.99 
Minimum 143 33 13.1 41 31 85.1 
Maximum 176 105 37.2 129 133 132.3 
 
The mean BMI of the population studied corresponds to obesity cut off by WHO classification 
of obesity. But the studies among the Asian Indian suggest lower BMI cut off for normal. This 
BMI corresponds to the high normal range according to the specific cut off for the BMI.  The 
normal WHR for Asians is less than 0.9.  
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Examination: 
The study population underwent a focussed examination. The pulse rate, blood pressures were 
recorded and tabulated as line plot (Figure 24)  
 
Figure 24: Blood pressure and Pulse rate of the study population. (Sys_BP – Systolic blood 
pressure in millimetres of mercurey, Pulse- pulse rate per minute.) 
 
Most of the study patients’ vitals were in the normal range, but the tachycardia in few patients is 
attributed to the high dose inhaled beta agonist along with high dose corticosteroids.  
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Laboratory parameters related to bone health: 
Patients who were included in the study underwent detailed laboratory assessment too. Their 
serum vitamin 25 OH-vitamin D3, which one of the important contributors to the bone 
metabolism was measured and was plotted (Figure 25).  
 
Figure 25: 25-hydroxy vitamin D3 of the study population. Serum level more than 30 
ng/mL is taken normal. Levels between 20-30 ng/mL is taken as insufficiency and less than 
20 ng/mL is taken as deficiency. 
The patients included in the study underwent early morning blood sample for serum calcium, 
iPTH and 25-hydroxy vitamin D levels (Figure 26). The samples were collected without 
52%
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23%
Deficiency Insufficency Normal
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tourniquet to avoid falsely high calcium level. The calcium was corrected for the serum albumin 
and the corrected calcium was used for analysis. 
 
Figure 26 Serum levels of iPTH, Calcium, alkaline phosphatase and vitamin D across the 
study population, iPTH-intact parathyroid hormone, vitamin D- 25-hydroxy vitamin D3 
As excepted 25-hydroxy vitamin D levels were low. But we also found increase in the serum 
iPTH level in 31% of the patient. The reason for this could be due to severe vitamin D 
deficiency with secondary hyperparathyroidism. 
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PRIMARY OUTCOME 
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Primary outcome  
The overall study outcome of osteopenia and Osteopenia in the COPD patient is shown below 
bar diagram (Figure 27)
 
Figure 27: Prevalence of low bone mineral density-osteoporosis and osteopenia. Overall 
prevalence of osteoporosis in this study is 61% 
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This result is again show in the form of table (Table 10) to emphasize the fact that the 
prevalence of osteoporosis in this study was as high as  61 percent(41/67) i.e. one in two patient 
with COPD who visits the ambulatory care of the tertiary care centre are osteoporotic. 
Table 10: Prevalence of osteoporosis in patients with COPD. The numbers represent the 
actual number of patient. N=67 
 
Regions  
 
T score <-2.5 
 
T score -1 to -2.5 
 
T score >-1.0 
Lumbar spine 16 30 21 
Femoral head 7 27 33 
Femoral neck 17 34 16 
Distal radius 22 22 23 
Any site 41 22 4 
 
 
 
CORRELATION OF LOW BONE MINERAL DENSITY (OSTEOPOROSIS AND 
OSTEOPENIA): 
The low bone mineral density is correlated with various predictors of adverse bone health   
 Age and osteoporosis  
 Smoking and bone health  
 Duration of COPD 
 Sunlight exposure and BMD 
96 
 
 Dietary calcium intake 
 Stage of COPD 
 BODE severity index 
 Inhaled steroid 
 Oral steroid 
 
First the prevalence of these abnormalities together is described and then the significance level 
is described by appropriate statistical test. 
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Age and osteoporosis: 
The prevalence of the osteoporosis increase as the age advances. This was studied and the age 
distribution of the patient was characterised in to two groups: more than 60 years and less than 
60 years. And as the age advance there was increased prevalence of osteoporosis even in our 
study (Figure 28).
 
Figure 28: Age and low bone health correlation. Increase in age increase the prevalenc of 
the osteoporosis.  
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Effect of smoking and bone health: 
The patient who were current smokers and reformed smokers were classified according to 
number of pack years and are divided into two categories as explained above and was then 
compared with bone mineral density (Figure 29) 
 
Figure 29: Smoking and bone mineral density correlation. Increase in smoking shows 
increasing trend toward adverse bone health 
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Duration of COPD and BMD: 
Longer the duration of disease, the more common is the systemic side effect. This is especially 
true for chronic disease like COPD. (Figure 30) 
 
Figure 30 Duration of COPD and bone mineral density correlation. Increase in duration 
of the disease show a trend towards increasing adverse bone health 
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Effect of sunlight exposure and osteoporosis and osteopenia: 
There is significant proportion of patient who did not have adequate sunlight exposure. The 
sunlight exposure is calculated according to method describe above in the methods sections.  
 
 
Figure 31:  Daily sunlight exposure and bone health correlation. <30 -less than minutes 
per day and > 30- more than 30 minutes per day 
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There is a positive correlation between the amount of sunlight exposure and the bone health. In 
the group less than 30 minutes there is increasing trend towards more patients with osteoporosis 
and osteopenia (Figure 31). 
Dietary calcium intake and osteoporosis: 
The dietary calcium intake was calculated according to the 24 hours dietary recall method. The 
dietary intake of calcium is the necessary raw material for the adequate bone strength.  
 
 
Figure 32: Dietary calcium intake and bone health correlation 
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The low dietary calcium intake was positively correlated with poor bone health (Figure 32). 
Although the dietary intake is less but there was only very small number of patient with 
hypocalcaemia. This may be due to method used to assess the dietary calcium intake. The more 
appropriate would to measure urine calcium and assess the calcium balance. 
Disease severity and osteoporosis: 
The correlation of disease severity contributing to the systemic side effects is due to two main 
reasons: 
o Increased systemic spill over of the inflammation 
o Increased used of steroid to control the disease 
The severity of the disease is estimated based on two things GOLD staging (Figure 33) and the 
prognostic index is the BODE index (Figure 34). 
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Figure 33: GOLD staging and bone mineral density correlation. 
 
The better predictive scoring is the BODE severity index which associates disease severity with 
the mortality at two years. As the disease severity increases, there is increase in the 
complications as expected (Figure 34)  
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Figure 34: BODE severity index and osteoporosis correlation 
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Treatment and BMD correlation: 
 It was previously seen in the above discussions that the dose of inhaled steroids was positively 
correlated with osteoporosis.  In this study we noticed the similar trend 
 
Figure 35: Inhaled steroid cumulative daily dose with severity of bone health. MDI-
metered dose inhaler. 
 
As the daily steroid intake increase there is a positive correlation with poor bone health. This is 
because higher dose are used in more severe patient, these patient tend to have more severe 
systemic complication and increase systemic spill over of the inhaled steroids (Figure 35).  
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This is also true for the total lifetime dose of inhaled steroid intake. The total lifetime dose of 
steroid intake is positively correlated with the increased risk of osteoporosis and osteopenia 
(Figure 36) 
 
Figure 36: Cumulative lifetime steroid intake and the prevalence of osteoporosis and 
osteopenia 
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The increased risk for osteoporosis with increased cumulative steroid intake may be due to 
multiple reason- increased duration of disease, difficulty in controlling the symptoms and 
erinaceous prescription of medicine  
Oral steroids 
The intake of oral steroid increases the adverse systemic complications one of which is 
osteoporosis (Figure 37). The intake was high in poorly controlled disease, refractory COPD and 
frequent exacerbation
 
Figure 37 oral steroids and bone health correlation 
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Statistical test of significance 
All the parameters which showed increased prevalence among the COPD patient were included 
for test of significance.  Pearson correlation –r and the t tailed p, was calculated. (Table 11) 
Table 11 two tailed p value for the bone mineral density  
Categories  LS spine Femoral neck  Femoral head Distal radius  
Age  0.182 0.192 0.409 0.019 
BMI 0.003 0.000 0.001 0.001 
Smoking  0.405 0.214 0.873 0.576 
Inhaled steroids 0.833 0.542 0.423 0.800 
Oral steroids 0.408 0.621 0.631 0.726 
Sunlight 
exposure 
0.870 0.193 0.431 0.160 
Dietary calcium 
intake 
0.723 0.277 0.461 0.553 
BODE index 0.625 0.234 0.407 0.949 
GOLD stage  0.063 0.345 0.439 0.868 
 
109 
 
Person chi square test was performed with two tailed p value. The odds ratio and confidence 
interval were calculated  
Table 12: Multivariate analysis of the variables associated with adverse bone health bone 
health. (C.I.  – 95% confidence interval) 
Categories chi-square p-value odds ratio C.I. 
Age 2.23 0.208 0.469 0.173-1.275 
Inhaled steroids 
High vs. Low dose 
0.131 1 1.314 0.298-5.787 
Oral steroids 0.503 0.553 0.658 0.206-2.101 
Smoking pack years 
(<20 Vs. >20 pack years) 
0.002 1 0.977 0.356-2.678 
Sunlight exposure 
(<30 Vs. > 30 minutes) 
1.228 0.294 2.202 0.533-9.108 
Dietary calcium intake 
(<1gm vs. > 1gm/day) 
3.002 0.118 2.609 0.867-7.847 
GOLD Stage 3.502 0.094 0.315 0.091- 1.09 
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Chi square test was performed and none of the variable which showed increased prevalence 
among COPD patient with osteoporosis in the previous analysis showed statistical significance 
(Table 12). This may be because of the small sample size which requires large study at a later 
date. 
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DISCUSSION 
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DISCUSSION 
COPD is a systemic disease as established by the number of previous studies(1).  Although the 
most serious extra-pulmonary organ involvement is the cardiovascular system but the most 
common disorder is the metabolic disorder. The poor bone health in patient with COPD is risk 
factor for increased osteoporotic fracture as shown by the data from the TORCH trial(64).  The 
problem with defining the risk for osteoporosis depends on loco- regional food habits, life style 
factors and the disease per se in view of environment pollution.  To our knowledge this study 
was first to describe the all the parameters related to the adverse bone health in patient with 
Chronic obstructive pulmonary disease. This study clearly shows the increased prevalence of 
osteoporosis in COPD patient.  This is almost doubled the prevalence as seen in normal 
population in India(65).  In the following discussion we will enumerate the following in detail  
 Prevalence of osteoporosis  
 Predictors of osteoporosis  
 Diagnosis of osteoporosis 
 Treatment of osteoporosis in COPD 
Prevalence of osteoporosis in COPD: 
The prevalence of osteoporosis in our study was 61% this was almost equal to the prevalence 
that was obtained from the studies in India and in the western population(61–63).  The bone 
density was measured at four place distal radius, femoral head, femoral neck and lumbar spine 
in our study. According to WHO if the T –score at lumbar spine or femoral neck  less than -2.5 
it is defined as osteoporosis in the men above 50 years of age (24).  The prevalence we obtained 
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in our study is similar to the prevalence in the two studies published so far in India. The first 
one is the study done by  Bhattacharya et al from Kolkata which was done in 2011(62). The 
following are important conclusion from the study  
o Total of 37 patient with COPD were studied  
o Patients were in stage III and IV disease 
o Ultrasound bone densitometer was used for analysis  
The limitations of this study was already been discussed. Osteoporosis was present in 19 
(51.35%) and osteopenia in 8 patients (21.62%).  According to the author the prevalence of the 
osteoporosis was high as compare to the prevalence of osteoporosis in the same region in the 
normal subjects. 
The second Indian study which I am going to quote is the study done by Hattiholi et al from 
Karanataka (63). This study had the following characteristic features in compare and contrast to 
our study. 
o 102 COPD patients both male and female were included. 
o Prevalence of osteoporosis was 66.6% and osteopenia was 19.36%. 
o BMD measured at Lumbar spine using DXA bone densitometer.  
o Patients with low BMI, and female sex had increased risk for osteoporosis. 
There were lot of limitation with respect to this study. The study population included both 
female and male. Female gender was one of the predictive variables for increased prevalence for 
osteoporosis. There was no sensitivity analysis done. The prevalence of osteoporosis in 
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ambulatory post-menopausal women in India according to the study done by Paul et al is 48% at 
the lumbar spine. This is the major limitation as this factor would have skewed the result to 
increased prevalence of osteoporosis in the patient with COPD. The prevalence of osteoporosis 
is similar to what we had found in our study corrected for the methodological problems in the 
previous studies. This is similar to the multiple studies that were published from all over the 
world (Table 13). 
Table 13: Details of the studies in the western countries about the prevalence of 
osteoporosis and osteopenia in patient with COPD 
No. Year 
Proposed theme 
of the study 
Authorsand 
reference 
Study Design                   
& 
Sample size if 
relevant 
Prevalence of 
osteoporosis and 
osteopenia 
1 2007 
The prevalence of 
osteoporosis in 
patients with 
chronic obstructive 
pulmonary disease 
Jørgensen et 
al(55) 
 
Cross-sectional 
study 
54 patients 
 
23.7% and 40.7% 
2 2005 
Bone density 
improvement after 
lung volume 
reduction  in 
COPD emphysema 
subjects 
Mineo et al(66) 
 
Prospective 
cohort study 
35% and 49% 
115 
 
 
3 2003 
Should COPD 
patients be 
routinely evaluated 
for bone mineral 
density? 
 
Karadag F et 
al(67) 
 
Cross sectional 
study  
28 patient 
35% and 42% 
4 2008 
. Cytokines, bone 
turnover markers 
and weight change 
in lung transplant 
candidates 
Forli L et L(68) 
Cross sectional 
study 
40 
48% and 33% 
5 2004 
Associated loss of 
fat-free mass and 
bone mineral 
density in COPD 
patients 
CE Bolton et 
al(69) 
Cross sectional 
study 
80 
 
27% and 38% 
 
116 
 
6 2002 
Osteoporosis 
before lung 
transplantation  
O Tschopp et 
al(70) 
Cross sectional 
study  
16 
Osteoporosis 69% and 
osteopenia not reproted 
7 2007 
Low bone mineral 
density in COPD 
Vrieze et al(71) 
Cross sectional 
study 
115 
8.7% and 40.9% 
8 2009 TORCH trial 
Ferguson GT et 
al(64) 
Prospective 
study 
658  
 
18% and 42 % 
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In all the above mentioned studies few important conclusions can be drawn 
o Prevalence of osteoporosis varies between different population studies  
o Prevalence of osteoporosis and osteopenia is in the range of 9-69% and 27-67% 
respectively. 
o The studies also confirmed that the following were the risk factors for bone health such 
as 
o  advanced age,   
o advanced disease, 
o  severity of disease  
o low BMI 
o Increased cumulative steroid  use 
o Oral steroid intake 
o Low fat free mass 
o Low FEV1 
These risk predictors for the adverse bone health is not consistent across all studies. In our study 
there was trend towards poor bone health in in age more than 60 years and low BMI. These 
predictors are interconnected with demographic profile of the patient studied and also the 
different treatment modality and concentration of the steroids in these modalities  
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LIMITATIONS 
These are the limitations that we found in our study: 
1. A major limitation of our study was a small sample size which prevents us from 
generalizing the results to all COPD patients. Further the patients were unequally 
distributed according to the severity of disease (as per GOLD criteria). This makes 
subgroup analysis according to different stages of COPD difficult. 
 
 
2. There was no age matched control group for comparasion hence it is difficult to interpret 
the statistical significance of our results.  
 
 
3. The study was conducted in a tertiary care hospital where patient profile (in terms of 
disease severity and comorbid conditions) is different compares to the general 
population  
 
 
4. Another limitation was cross-sectional design of the study hence the clinical impact of 
the results of the study could not be measured.  
 
 
5. Majority of the subjects included in the current study were South Indian men; hence, the 
results could be applied only to this population.  Various parameters included in this 
study are liable to get affected by gender, ethnicity as well as food habits. 
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RECOMMENDATION AND FUTURE DIRECTIONS 
 
Given the high prevalence of low bone mass detected in our study group it is without hesitation 
that we recommend evaluation of all COPD patients for bone health. We also recommend future 
work in the following areas will benefit the patient care  
o To study the osteoporotic risk in the female COPD patients 
 
o Prospectively follow up of COPD patient with osteoporosis atleast for a minimum of 10 
years 
 
o Formulation of fracture risk score in COPD patient with osteoporosis  
 
o Inclusion of COPD as a risk factor in the WHO FRAX algorithm 
 
 
o Randomised controlled trials to study the effect of pulmonary rehabilitation on the bone 
health in patient with COPD 
 
o An intervention to study the effect of bone medication in the disease outcome in COPD 
patient with Osteoporosis 
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CONCLSUIONS 
 
The aim of the study was achieved: 
A. The prevalence of osteoporosis among male patients with chronic obstructive pulmonary 
disease visiting the tertiary care centre was studied and was found to be 61% (41/67).  In 
simple terms one in two patient with COPD has osteoporosis 
B. The factor which showed trends towards adverse bone health in COPD patients were: 
i. Advanced age 
ii. Low body mass index 
 
C. Osteopenia was present in  33% (22/67) of the study population 
 
D. Only 6%(4/67) of the study population had normal values for the bone mineral density  
 
 
E. The prevalence of metabolic bone abnormality in patient with COPD in this study were  
i. Vitamin D deficiency in 69 %( 46/67),  
ii. Hypocalcaemia in 4 %( 3/67) and 
iii. Raised alkaline phosphatase and parathormone in 8% (6/67) and 31 %( 21/67) 
respectively. 
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Annexure I- Patient information and consent form 
 
PARTICIPANT INFORMATION SHEET 
 
Christian Medical College & Hospital, Vellore 
 
You are being invited to participate in a research study.  Your participation in this study is 
entirely voluntary.  Your decision whether or not to participate will have no effect on the quality 
of medical care you will receive in this hospital. 
 
An investigator in this study will explain the purpose of this study including how this study will 
be carried out and your contribution or role in the study.  The paragraphs below explain the 
study.  Please ask questions if there is anything you do not understand before you decide to 
participate in this study. 
 
STUDY TITLE 
BONE HEALTH IN CHRONIC OBSTRUCTIVE AIRWAY DISEASES. 
 
PRINCIPAL INVESTIGATOR:  Dr. Mohammad Sadiq.J 
 
 
What is the purpose of this study? 
This study plans to look bone health in male patient with chronic obstructive airway disease.  It 
is well known fact that COPD and its treatment affect the bone health. But there is no Indian 
study to show how common is this problem in Indian population.  
 
What does this study involve? 
The blood samples will be tested for parameters related to bone health. Other tests which 
includes chest x-ray, lumbo-sacral spine x-ray, DXA scan, 6MWT (six minute walk test) and 
spirometry which are related to disease will be tested.   
 
Are there any benefits from participating in this study? 
These tests will provide an existing bone health of your body.  If there is any abnormality 
detected in any of the test you will be informed if you want to know the results. We will not 
provide treatment as part of this study and you will be treated in this hospital if you wish to do 
so as any general medical condition. This study is helpful for science and humanity.  
 
What are the risks involved in participating in this study? 
Participating in this study does not affect your health in any adverse manner.  You will receive 
the same standard care regardless of your willingness to participate in the study.  
 
Will my taking part in this study be kept confidential? 
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 All information collected about you during the course of research will be kept strictly 
confidential. Any information which leaves the hospital/clinic/laboratory will have your name 
and address removed so that you cannot be recognized from it. 
 
 
What will happen to the results of the research study? 
Results of the research will be published in national/international journals. We are also assuring 
you that you will not be identified in any report/publication. 
 
 If the above information does not provide answers to your questions, request the investigator to 
answer them for you.  Also, this sheet is for your information and you can retain this copy with 
you. 
 
 
Contact for further information- 
For further information kindly contact- 
                 Dr Mohammad Sadiq.J, 
                 PG Registrar Department of General Medicine 
                 Christian Medical College and Hospital, Vellore -632004,  
                 Tamil Nadu, India. 
                 Ph no:  09443045199 
                  Email: mohammadsadiqj@gmail.com 
 
 
Thank you for taking part in this research study. 
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CONSENT FORM 
 
 
Christian Medical College & Hospital, Vellore.  
 
 
STUDY TITLE 
 
BONE HEALTH IN CHRONIC OBSTRUCTIVE AIRWAY DISEASES 
PRINCIPAL INVESTIGATOR 
Dr. Mohammad Sadiq J 
 
                      
A. I _____________, understand that the physicians at the department of Medicine, 
Endocrinology and Pulmonary Medicine, Christian Medical College are engaged in research 
on the nature, diagnosis and treatment of Diabetes. 
  
B. I have been informed that this study involves research and that the purpose is to assess the 
bone health in COPD patient  
 
C. I understand that a sample of blood (10ml) will be drawn once for research purposes and not 
as a routine clinical test, and that this blood sample may be stored and used in the laboratory 
for many years, in relation to treatment objectives of this study until it is used up. A chest x-
ray and DXA scan will also be taken. 
 
D. I understand that the possible discomforts and risks attendant to this procedure include some 
degree of pain from the insertion of the needle into the vein and radiation exposure, but this 
is usually minimal.  An occasional patient faints due to blood sampling procedure, and 
rarely there is some discomfort for a few days at the site of venipuncture due to the 
formation of a bruise.  If any tests are performed on my blood, I will be told which tests 
have been performed and the results could be made available to me. 
 
E. I understand that the records connected with my participation in the clinical investigation 
will be kept strictly confidential.  My name will not be revealed in any publication that may 
arise from this study. 
 
F. I have had the opportunity to ask questions concerning the procedures to be used.  I 
understand that if I have any further questions concerning the research conducted, I may 
contact Dr. Mohammad Sadiq. J or his co-investigators in the department Medicine, 
Endocrinology and Pulmonary medicine, Christian Medical College, and Vellore. 
 
G. I further understand that I am free to withdraw my consent at any time without any penalty 
or loss of benefits to which I may be otherwise entitled.  I  also will not be paid for 
participation in this study but there will be no additional cost to me for evaluations 
necessary for this study  
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H. I hereby voluntarily consent to participate in this study and to allow the procedures 
described above to be performed on me. 
 
 
 
______________________________                                    ___________________ 
                Signature of Subject                                                               Date 
 
   OR 
 
 
 
 
 
 
 Thumb Impression 
 
 
        INVESTIGATOR'S OR SUB-INVESTIGATORS STATEMENT 
 
 I have offered an opportunity for further explanation of this procedure to the individual 
whose signature appears above. 
       ______________________________ 
Note:  The subject shall be given a copy of this consent form.  A signed copy must be filled 
in the patient's file at the Department of Endocrinology, Christian Medical College & 
Hospital,Vellore. 
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Annexure II- Data abstraction form 
 
 
SR NO:__________                                                                          Date_____________ 
THE BOAD STUDY 
DEMOGRAPHIC DATA 
Age  Hospital No   
Occupation  Tel No: 
Address:  
HISTORY 
COPD HISTORY 
Duration  
GOLD COPD Stage (Appendix 1)  
BODE severity index(Appendix 2)  
  
COPD TERATMENT HISTORY 
Inhaled steroids   
Drug   
Dose   
Duration  
Last dose  
Oral steroids   
Drug   
Dose   
Duration   
Last dose  
SMOKING HISTORY 
Pack-years   
Current smoker Yes/No 
If no stopped smoking since  ____________months 
OTHER RELEVANT HISTORY 
136 
 
 
Backache   
Duration  ____________years 
Treatment  Calcium, Vitamin D/ Bisphosphonates 
History of fracture  
Sun-light exposure duration  
History of loss of libido Yes/No 
Diabetes Yes/No 
Duration  ____________years 
Treatment  OADS/Insulin/Both 
Hypertension Yes/No 
Duration  ____________years 
Treatment Yes/No 
Dyslipidemia  Yes/No 
Treatment Yes/No 
DIET AND PHYSICAL ACTIVITY 
Dietary recall  __________Kcal/day 
Dietary calcium intake  
RELEVANT EXAMINATION 
 
Weight (Kg) Systolic BP (mmHg) 
Height (cm) Diastolic BP (mmHg) 
BMI (kg/m2)  
Waist circumference (cm)  
W/H ratio(___cm/___cm)  
SPIROMETRY 
 
FEV1  
FVC  
FEV1/FVC  
6 MWT  
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\ 
 
 
 
 
 
 
 
 
 
 
 
 
 
INVESTIGATIONS 
 
Calcium  
Phosphorus  
Albumin  
Alkaline phophotase  
25 hydroxy-vitamin D  
Creatinine  
Testosterone  
iPTH  
      DXA 
                         
  
T score 
Femoral Head  
Lumbar spine  
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GOLD Stage Spirometry 
I FEV1/FVC <0.7 and FEV1 80% predicted 
  
II FEV1/FVC <0.7 and 50% FEV1 <80% predicted 
  
III FEV1/FVC <0.7 and 30% FEV1 <50% predicted 
  
IV FEV1/FVC <0.7 and FEV1 <30% predicted 
or 
FEV1 <50% predicted with respiratory failure or signs of right heart failure 
 
 
 
 
 
Parameter 0 1 2 3 
BMI  >21 ≤21 — — 
Obstruction: FEV
1
 (% 
predicted)  
≥65% 50–64% 36–49% ≤35% 
Dyspnea: MMRC score  0-1 2 3 4 
Exercise: 6-minute walk 
distance (meters)  
≥350 250–349 150–249 ≤149 
     
 
 
Appendix 1: GOLD classification of COPD  
Appendix 2: BODE disease severity index 
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Annexure III- Data sheet 
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Annexure IV-Standard operation protocol 
 
 
 
 
 
 
 
GOLD Stage Spirometry 
I FEV1/FVC <0.7 and FEV1 80% predicted 
 
II FEV1/FVC <0.7 and 50% FEV1 <80% predicted 
 
III FEV1/FVC <0.7 and 30% FEV1 <50% predicted 
 
IV FEV1/FVC <0.7 and FEV1 <30% predicted 
or 
FEV1 <50% predicted with respiratory failure or signs of right heart failure 
 
 
 
 
 
 
 
Standard operation protocol: GOLD classification of COPD  
143 
 
 
 
 
 
 
 
 
 
 
Parameter 0 1 2 3 
BMI >21 ≤21 — — 
Obstruction: FEV
1
 (% predicted) ≥65% 50–64% 36–49% ≤35% 
Dyspnea: MMRC score 0-1 2 3 4 
Exercise: 6-minute walk distance 
(meters) 
≥350 250–349 150–249 ≤149 
 
Standard operation protocol 2: BODE disease severity index 
